Ardea Biosciences’ Lead MEK Inhibitor, RDEA119, To Enter Human Clinical Trials In Advanced Cancer Patients
Ardea Biosciences, Inc. (Pink Sheets: ARDC), a company focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) granted safe-to-proceed status to the Investigational New Drug (IND) application for RDEA119, enabling initiation of a Phase 1 clinical trial in advanced cancer patients. [click link for full article]
More: continued here
Filed under: Clinical Trials on October 5th, 2007